Alexion acquires Portola for $1.41 billion dollars
Alexion acquires Portola for $1.41 billion dollars
… Alexion Expands Its Rare Disease Pharmaceutical Enterprise …


Andexxa (coagulation factor Xa (recombinant), inactivated-zhzo) coveted as the only approved FaxtorXa inhibitor reversal agent

John G. Baresky

Alexion Pharmaceuticals (NASDAQ: ALXN) has announced it is acquiring Portola Pharmaceuticals (NASDAQ: PTLA) for $1.41 billion in cash. Founded in 2003, Portola is based in South San Francisco and produces about $116 million in annual sales.

As a biotechnology company, Portola specializes in thrombotic and other hematologic disorders

Andexxa (coagulation factor Xa (recombinant), inactivated-zhzo) is a recombinant modified human factor Xa (FXa) protein indicated for patients treated with rivaroxaban or apixaban when reversal of anticoagulation is needed due to life-threatening or uncontrolled bleeding. It is administered through IV infusion.

Portola’s pipeline candidates include:

  • Andexanet Alfa: seeking indications for the reversal of other Factor Xa inhibitors and urgent surgery
  • Cerdulatinib is a dual-spleen tyrosine kinase and janus kinase (SYK/JAK) inhibitor with potential to gain indications for peripheral T-cell lymphoma (PTCL), cutaneous T-cell lymphoma (CTCL) and follicular lymphoma

Alexion is a leader centered on the creation of novel, advanced biotherapies

In April 2020, Alexion launched a phase 3 study to investigate the safety and efficacy of Ultomiris (ravulizumab‑cwvz), a monoclonal antibody C5 inhibitor as a treatment for COVID-19. The product is presently FDA approved for the treatment of paroxysmal nocturnal hemoglobinuria, a rare blood disease that triggers red blood cells to break apart and release hemoglobin (the carrier in red blood cells that transports oxygen to cells).

The unique and highly advanced products within Portola’s portfolio and pipeline are an ideal fit for Alexion’s focus on rare diseases.

Thank you for reading this story

Read my other articles about medical and healthcare business trends, content marketing and digital strategy, brand and product management, consumer wellness, managed care and market access strategy. Contact me today for your healthcare content writing and content strategy needs.

I have over 20 years of experience in the healthcare industry producing valuable healthcare content for audiences and customers spanning physicians, nurses, pharmacists plus pharmaceutical companies, medical technology manufacturers, healthcare provider organizations, managed care, investors, consumers and other stakeholders.

Visit and connect…




Google My Business

As a healthcare content writer, my work aligns with an organization’s voice, brand, SEO elements, marketplace and objectives. It establishes trust in their company and recognized value in its products and services that generates revenue.

This experience was earned through working at Walgreens, Pfizer, AbelsonTaylor, TAP (Takeda Abbott Partnership), Hospira Worldwide and Boston Software Systems. ​

To a large degree, my professional interests emulate my family which includes doctors, nurses, physician assistants and other clinicians plus those that are working in healthcare administration and commercial enterprises.

Bare Sky Marketing LinkedIn Business Profile

See this article on Slide Share!

Written by

Authentic, fact-based healthcare content marketing writing for medical, business, academic, patient and consumer audiences

Get the Medium app

A button that says 'Download on the App Store', and if clicked it will lead you to the iOS App store
A button that says 'Get it on, Google Play', and if clicked it will lead you to the Google Play store